Are CD4⁺ T-Cell Counts Associated with Pneumocystis jirovecii Detection in Hospitalized Patients with Liver Disease? A Retrospective Exploratory Pilot Analysis

Keyphrases

• CD4+ T 100%
• Hospitalized Patients 100%
• Cell Count 100%
• Pneumocystis Jirovecii 100%
• Patients with Liver Disease 100%
• Immunological Risk 100%
• Risk Cluster 88%
• CD4+ 27%
• Cirrhotic Patients 16%
• Cirrhosis 11%
• Opportunistic Infections 11%
• Cell Depletion 11%
• In-hospital Mortality 11%
• Risk Stratification 5%
• Clinical Outcomes 5%
• HIV Patients 5%
• HIV Positivity 5%
• Advanced Cirrhosis 5%
• Clinical High Risk 5%
• Trimethoprim-sulfamethoxazole (TMP-SMX) 5%
• Bacterial Infection 5%
• HIV+ 5%
• Hepatic Disease 5%
• Risk Threshold 5%
• Risk Strata 5%
• PCR Test 5%
• Hepatic Decompensation 5%
• Risk Criteria 5%
• Ct Value 5%
• Guiding Strategy 5%
• Immune Dysregulation 5%
• Single Institution 5%
• Prospective multicenter Study 5%
• Splenic Sequestration 5%
• Pneumonia Risk 5%
• Non-HIV Immunocompromised 5%

Immunology and Microbiology

• CD4 Lymphocyte Count 100%
• Pneumocystis Jiroveci 100%
• Human Immunodeficiency Virus 60%
• CD4 60%
• Cirrhosis 30%
• T-Helper Cell 20%
• Opportunistic Infection 20%
• Hospital Mortality 20%
• T Cell Depletion 20%
• Immune Dysregulation 10%
• Infectious Disease 10%
• Infection 10%